Arcus Biosciences, Inc. (NYSE: RCUS) Stock Competitors & Peer Comparison

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while VRTX trades at $477.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas VRTX's P/E ratio is 25.36. In terms of profitability, RCUS's ROE is -0.69%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RCUS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VRTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RCUS's ROE is -0.69%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RCUS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VRNA's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while REGN trades at $656.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas REGN's P/E ratio is 14.38. In terms of profitability, RCUS's ROE is -0.69%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RCUS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check REGN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ARGX has a market cap of 57.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ARGX trades at $918.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ARGX's P/E ratio is 82.87. In terms of profitability, RCUS's ROE is -0.69%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, RCUS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ARGX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RCUS's ROE is -0.69%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RCUS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SGEN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RVMDW trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RVMDW's P/E ratio is -2.29. In terms of profitability, RCUS's ROE is -0.69%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RCUS is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RVMDW's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RVMD trades at $189.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RVMD's P/E ratio is -26.77. In terms of profitability, RCUS's ROE is -0.69%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RCUS is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RVMD's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ALNY has a market cap of 36.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ALNY trades at $271.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ALNY's P/E ratio is 48.97. In terms of profitability, RCUS's ROE is -0.69%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RCUS is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALNY's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ONC trades at $325.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ONC's P/E ratio is 72.91. In terms of profitability, RCUS's ROE is -0.69%, compared to ONC's ROE of +0.12%. Regarding short-term risk, RCUS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ONC's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ROIV trades at $35.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ROIV's P/E ratio is -35.99. In terms of profitability, RCUS's ROE is -0.69%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RCUS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ROIV's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while INCY trades at $117.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas INCY's P/E ratio is 15.82. In terms of profitability, RCUS's ROE is -0.69%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RCUS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check INCY's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while INSM trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas INSM's P/E ratio is -18.59. In terms of profitability, RCUS's ROE is -0.69%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RCUS is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check INSM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BNTX trades at $89.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BNTX's P/E ratio is -19.34. In terms of profitability, RCUS's ROE is -0.69%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RCUS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BNTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while UTHR trades at $528.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas UTHR's P/E ratio is 19.51. In terms of profitability, RCUS's ROE is -0.69%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RCUS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check UTHR's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MRNA trades at $54.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MRNA's P/E ratio is -6.63. In terms of profitability, RCUS's ROE is -0.69%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RCUS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check MRNA's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RCUS's ROE is -0.69%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RCUS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BGNE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RCUS's ROE is -0.69%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RCUS is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DNA-WT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas GMAB's P/E ratio is 20.77. In terms of profitability, RCUS's ROE is -0.69%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RCUS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check GMAB's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while NBIX trades at $175.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas NBIX's P/E ratio is 25.40. In terms of profitability, RCUS's ROE is -0.69%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RCUS is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check NBIX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BBIO trades at $84.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BBIO's P/E ratio is -22.47. In terms of profitability, RCUS's ROE is -0.69%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RCUS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BBIO's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while JAZZ trades at $253.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas JAZZ's P/E ratio is 19.74. In terms of profitability, RCUS's ROE is -0.69%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RCUS is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check JAZZ's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ASND trades at $253.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ASND's P/E ratio is -104.90. In terms of profitability, RCUS's ROE is -0.69%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RCUS is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ASND's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, EXEL has a market cap of 13.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while EXEL trades at $55.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas EXEL's P/E ratio is 16.58. In terms of profitability, RCUS's ROE is -0.69%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RCUS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check EXEL's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RCUS's ROE is -0.69%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RCUS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KRTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MDGL trades at $544.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MDGL's P/E ratio is -42.54. In terms of profitability, RCUS's ROE is -0.69%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RCUS is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MDGL's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while AXSM trades at $241.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas AXSM's P/E ratio is -62.92. In terms of profitability, RCUS's ROE is -0.69%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RCUS is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check AXSM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ARWR trades at $85.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ARWR's P/E ratio is -39.81. In terms of profitability, RCUS's ROE is -0.69%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RCUS is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ARWR's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BMRN trades at $59.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BMRN's P/E ratio is 28.52. In terms of profitability, RCUS's ROE is -0.69%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RCUS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BMRN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RCUS's ROE is -0.69%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RCUS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RNAM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while TECH trades at $71.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas TECH's P/E ratio is 36.91. In terms of profitability, RCUS's ROE is -0.69%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RCUS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TECH's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while SMMT trades at $13.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas SMMT's P/E ratio is -8.54. In terms of profitability, RCUS's ROE is -0.69%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, RCUS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check SMMT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CYTK trades at $80.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CYTK's P/E ratio is -13.85. In terms of profitability, RCUS's ROE is -0.69%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RCUS is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CYTK's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while KRYS trades at $335.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas KRYS's P/E ratio is 44.81. In terms of profitability, RCUS's ROE is -0.69%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RCUS is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KRYS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while HALO trades at $81.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas HALO's P/E ratio is 17.73. In terms of profitability, RCUS's ROE is -0.69%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RCUS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check HALO's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RCUS's ROE is -0.69%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RXDX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while IONS trades at $56.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas IONS's P/E ratio is -32.88. In terms of profitability, RCUS's ROE is -0.69%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RCUS is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IONS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ABVX trades at $125.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ABVX's P/E ratio is -65.89. In terms of profitability, RCUS's ROE is -0.69%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RCUS is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ABVX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas NUVL's P/E ratio is -21.79. In terms of profitability, RCUS's ROE is -0.69%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RCUS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check NUVL's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while KYMR trades at $110.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas KYMR's P/E ratio is -31.32. In terms of profitability, RCUS's ROE is -0.69%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RCUS is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check KYMR's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CRNX trades at $83.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CRNX's P/E ratio is -16.32. In terms of profitability, RCUS's ROE is -0.69%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RCUS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CRNX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ALKS trades at $52.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ALKS's P/E ratio is 55.67. In terms of profitability, RCUS's ROE is -0.69%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RCUS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALKS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while PTGX trades at $136.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas PTGX's P/E ratio is -75.20. In terms of profitability, RCUS's ROE is -0.69%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RCUS is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PTGX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RCUS's ROE is -0.69%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RCUS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IMGN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while TGTX trades at $56.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas TGTX's P/E ratio is 19.26. In terms of profitability, RCUS's ROE is -0.69%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RCUS is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TGTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RCUS's ROE is -0.69%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BPMC's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while APGE trades at $134.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas APGE's P/E ratio is -31.01. In terms of profitability, RCUS's ROE is -0.69%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RCUS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check APGE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, RCUS's ROE is -0.69%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RCUS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CERE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while IMVT trades at $39.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas IMVT's P/E ratio is -14.76. In terms of profitability, RCUS's ROE is -0.69%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RCUS is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IMVT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while PCVX trades at $54.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas PCVX's P/E ratio is -7.94. In terms of profitability, RCUS's ROE is -0.69%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RCUS is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PCVX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while IBRX trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas IBRX's P/E ratio is -8.35. In terms of profitability, RCUS's ROE is -0.69%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RCUS is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check IBRX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RCUS's ROE is -0.69%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RCUS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MTSR's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RYTM trades at $102.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RYTM's P/E ratio is -32.62. In terms of profitability, RCUS's ROE is -0.69%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RCUS is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RYTM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while PRAX trades at $325.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas PRAX's P/E ratio is -24.33. In terms of profitability, RCUS's ROE is -0.69%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RCUS is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PRAX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RCUS's ROE is -0.69%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RCUS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MRUS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while COGT trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas COGT's P/E ratio is -18.84. In terms of profitability, RCUS's ROE is -0.69%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RCUS is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check COGT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RCUS's ROE is -0.69%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RCUS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ACLX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ERAS trades at $19.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ERAS's P/E ratio is -20.55. In terms of profitability, RCUS's ROE is -0.69%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RCUS is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ERAS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, RCUS's ROE is -0.69%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RCUS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RETA's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while PTCT trades at $76.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas PTCT's P/E ratio is -32.97. In terms of profitability, RCUS's ROE is -0.69%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RCUS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check PTCT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RCUS's ROE is -0.69%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RCUS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CNTA's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while SYRE trades at $102.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas SYRE's P/E ratio is -49.10. In terms of profitability, RCUS's ROE is -0.69%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SYRE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while BLTE trades at $153.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas BLTE's P/E ratio is -82.01. In terms of profitability, RCUS's ROE is -0.69%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, RCUS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check BLTE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CGON trades at $69.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CGON's P/E ratio is -29.75. In terms of profitability, RCUS's ROE is -0.69%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RCUS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CGON's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while LGND trades at $300.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas LGND's P/E ratio is 36.03. In terms of profitability, RCUS's ROE is -0.69%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RCUS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check LGND's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while SRRK trades at $47.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas SRRK's P/E ratio is -13.28. In terms of profitability, RCUS's ROE is -0.69%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RCUS is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SRRK's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MIRM trades at $113.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MIRM's P/E ratio is -8.30. In terms of profitability, RCUS's ROE is -0.69%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RCUS is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MIRM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RCUS's ROE is -0.69%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RCUS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CDTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RCUS's ROE is -0.69%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RCUS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ABCM's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RCUS's ROE is -0.69%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RCUS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ISEE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while TVTX trades at $57.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas TVTX's P/E ratio is -260.73. In terms of profitability, RCUS's ROE is -0.69%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RCUS is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TVTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas APLS's P/E ratio is 38.35. In terms of profitability, RCUS's ROE is -0.69%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RCUS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check APLS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while XENE trades at $65.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas XENE's P/E ratio is -13.92. In terms of profitability, RCUS's ROE is -0.69%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RCUS is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check XENE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas TERN's P/E ratio is -51.41. In terms of profitability, RCUS's ROE is -0.69%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RCUS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TERN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while DFTX trades at $43.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas DFTX's P/E ratio is N/A. In terms of profitability, RCUS's ROE is -0.69%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, RCUS is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DFTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MANE trades at $109.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MANE's P/E ratio is -34.92. In terms of profitability, RCUS's ROE is -0.69%, compared to MANE's ROE of -0.84%. Regarding short-term risk, RCUS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check MANE's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RCUS's ROE is -0.69%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RCUS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check FOLD's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RCUS's ROE is -0.69%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RCUS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check AKRO's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CRSP trades at $46.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CRSP's P/E ratio is -9.11. In terms of profitability, RCUS's ROE is -0.69%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RCUS is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CRSP's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RCUS's ROE is -0.69%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RCUS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ALPN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while EWTX trades at $40.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas EWTX's P/E ratio is -24.60. In terms of profitability, RCUS's ROE is -0.69%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RCUS is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check EWTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CAI trades at $15.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CAI's P/E ratio is -85.37. In terms of profitability, RCUS's ROE is -0.69%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RCUS is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CAI's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while DNTH trades at $103.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas DNTH's P/E ratio is -25.15. In terms of profitability, RCUS's ROE is -0.69%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RCUS is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DNTH's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ACAD trades at $24.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ACAD's P/E ratio is 12.18. In terms of profitability, RCUS's ROE is -0.69%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RCUS is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ACAD's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, RCUS's ROE is -0.69%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RCUS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check OPT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RCUS's ROE is -0.69%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RCUS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check MRTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while LEGN trades at $22.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas LEGN's P/E ratio is -32.68. In terms of profitability, RCUS's ROE is -0.69%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RCUS is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check LEGN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while DYN trades at $24.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas DYN's P/E ratio is -7.59. In terms of profitability, RCUS's ROE is -0.69%, compared to DYN's ROE of -0.58%. Regarding short-term risk, RCUS is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DYN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while VKTX trades at $34.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas VKTX's P/E ratio is -8.40. In terms of profitability, RCUS's ROE is -0.69%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RCUS is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check VKTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CELC has a market cap of 4B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CELC trades at $82.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CELC's P/E ratio is -21.18. In terms of profitability, RCUS's ROE is -0.69%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RCUS is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check CELC's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CPRX's P/E ratio is 12.30. In terms of profitability, RCUS's ROE is -0.69%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RCUS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CPRX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ELVN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ELVN's P/E ratio is -31.71. In terms of profitability, RCUS's ROE is -0.69%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, RCUS is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ELVN's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RCUS's ROE is -0.69%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RCUS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check RYZB's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RCUS's ROE is -0.69%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RCUS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check CBAY's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while DNLI trades at $23.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas DNLI's P/E ratio is -8.02. In terms of profitability, RCUS's ROE is -0.69%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RCUS is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check DNLI's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while NAMSW trades at $19.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, RCUS's ROE is -0.69%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, RCUS is less volatile compared to NAMSW. This indicates lower risk in terms of short-term price fluctuations for RCUS.Check NAMSW's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while ADPT trades at $22.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas ADPT's P/E ratio is -41.24. In terms of profitability, RCUS's ROE is -0.69%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, RCUS is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check ADPT's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RCUS's ROE is -0.69%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, RCUS is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check SWTX's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while NAMS trades at $29.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas NAMS's P/E ratio is -18.64. In terms of profitability, RCUS's ROE is -0.69%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RCUS is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check NAMS's competition here

Arcus Biosciences, Inc. (NYSE: RCUS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RCUS stands at 2.9B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, RCUS is priced at $28.42 on the NYSE, while TLX trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RCUS currently has a P/E ratio of -8.73, whereas TLX's P/E ratio is -555.43. In terms of profitability, RCUS's ROE is -0.69%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RCUS is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for RCUS.Check TLX's competition here